LACK OF EFFECT FROM MITOMYCIN-C PLUS 5-FLUOROURACIL IN PLATIN-RESISTANT OVARIAN-CANCER - A PHASE-II STUDY

Sixteen patients with advanced ovarian cancer were included in a phase II study with mitomycin c (MMC) plus 5-fluorouracil (5-FU). All patie nts had previously received platin-based combination therapy, but were resistant to this treatment. A MMC 10 mg m(-2) intravenous (iv) bolus was given on day 1 every 6 weeks, and 5-FU 1000 mg m(-2) was given iv on days 1-3 every 3 weeks, as a continuous infusion over 72 h. Fiftee n patients were evaluable for response. There were no responders, neit her partial nor complete. The median survival was 6 months. The toxici ty was primarily bone marrow suppression. The treatment was generally well tolerated. No patients had grade 4 toxicity and only five had gra de 3 hematologic toxicity. In conclusion, we find the present regimen to be ineffective in the treatment of platin-resistant ovarian cancer.